We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lexeo Therapeutics Inc | NASDAQ:LXEO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -2.03% | 9.67 | 9.50 | 10.16 | 10.17 | 9.55 | 10.17 | 155,242 | 01:00:00 |
“We were proud to present the recent interim data of LX2006 for the treatment of FA cardiomyopathy, the first ever to show promise of treating this rare and fatal condition,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “Based on the favorable evidence to date, we have initiated engagements with FDA on surrogate endpoints for a registrational study so we can work to bring this potentially transformative gene therapy to patients as quickly as possible.”
Business and Program Updates
Expected Upcoming Milestones
Second Quarter Financial Results
About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
Cautionary Note Regarding Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regarding the potential benefits of LX2006 for the treatment of Friedreich ataxia cardiomyopathy and the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Annual Report on Form 10-K for the annual period ended December 31, 2023, filed with the SEC on March 11, 2024, Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 9, 2024, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Response:Janine Bogris(201) 245-6838janine.bogris@inizioevoke.com
Investor Response:Stephen Jasper(858) 525-2047stephen@gilmartinir.com
Lexeo Therapeutics, Inc.Selected Condensed Financial Information(unaudited, in thousands, except share and per share amounts) | ||||||||||||||||
Condensed Statements of Operations | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Operating expenses | ||||||||||||||||
Research and development | $ | 16,560 | $ | 11,236 | $ | 32,302 | $ | 27,674 | ||||||||
General and administrative | 6,990 | 2,739 | 14,539 | 5,592 | ||||||||||||
Total operating expenses | 23,550 | 13,975 | 46,841 | 33,266 | ||||||||||||
Operating loss | (23,550 | ) | (13,975 | ) | (46,841 | ) | (33,266 | ) | ||||||||
Other income and expense | ||||||||||||||||
Other income (expense), net | (1 | ) | (3 | ) | (6 | ) | (7 | ) | ||||||||
Interest expense | (35 | ) | (53 | ) | (72 | ) | (103 | ) | ||||||||
Interest income | 2,348 | 590 | 3,999 | 1,277 | ||||||||||||
Total other income and expense | 2,312 | 534 | 3,921 | 1,167 | ||||||||||||
Loss from operations before income taxes | (21,238 | ) | (13,441 | ) | (42,920 | ) | (32,099 | ) | ||||||||
Income taxes | - | - | - | - | ||||||||||||
Net loss and comprehensive loss | $ | (21,238 | ) | $ | (13,441 | ) | $ | (42,920 | ) | $ | (32,099 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.64 | ) | $ | (8.30 | ) | $ | (1.41 | ) | $ | (19.87 | ) | ||||
Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted | 33,001,946 | 1,619,547 | 30,490,892 | 1,615,194 |
Condensed Balance Sheet Data | ||||||||
June 30 | December 31, | |||||||
2024 | 2023 | |||||||
Cash and cash equivalents | $ | 174,981 | $ | 121,466 | ||||
Total assets | 192,007 | 139,807 | ||||||
Total liabilities | 27,059 | 26,272 | ||||||
Total stockholders' equity | 164,948 | 113,535 |
1 Year Lexeo Therapeutics Chart |
1 Month Lexeo Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions